Targets › TYMP
9 programs from 9 companies in 11 trials: 6 Phase 2, 5 Phase 1; Oncology; next expected readout Nov 2026.
May have a role in maintaining the integrity of the blood vessels. Has growth promoting activity on endothelial cells, angiogenic activity in vivo and chemotactic activity on endothelial cells in vitro..; FUNCTION: Catalyzes the reversible phosphorolysis of thymidine. (UniProt, P19971)
Open in Phaseline: the race on TYMP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Qilu Hospital of Shandong University | Tipiracil Thymidine phosphorylase inhibitor | TYMP | Phase 2 | Metastatic Colorectal Cancer | Dec 2026 |
| Ruijin Hospital | Trifluridine/tipiracil (TAS-102) Nucleoside antimetabolite; trifluridine is incorporated into DNA and tipiracil inhibits th | TYMP | Phase 2 | Colo-rectal Cancer | Aug 2027 |
| First Affiliated Hospital of Zhejiang University | Tipiracil Thymidine phosphorylase inhibitor | TYMP | Phase 2 | Esophageal Squamous Cell Carcinoma (ESCC) | Aug 2027 |
| Sun Yat-sen University | Tipiracil (TAS-102) Thymidine phosphorylase inhibitor | TYMP | Phase 2 | Rectal Cancer; Colorectal Cancer Metastatic | Dec 2027 |
| GERCOR - Multidisciplinary Oncology Cooperative Group | Tipiracil Thymidine phosphorylase inhibitor | TYMP | Phase 2 | Metastatic Colorectal Cancer | – |
| Gruppo Oncologico del Nord-Ovest | Tipiracil Thymidine phosphorylase inhibitor | TYMP | Phase 1 | Colorectal Cancer Metastatic | Nov 2026 |
| Yonsei University | Tipiracil Thymidine phosphorylase inhibitor | TYMP | Phase 1 | Gastric and Gastroesophageal Junction Adenocarcinoma | – |
| Emory University | Tipiracil (TAS-102) Thymidine phosphorylase inhibitor | TYMP | Phase 1 | Colorectal Adenocarcinoma | – |
| National University Hospital, Singapore | Tipiracil (TAS-102) Thymidine phosphorylase inhibitor | TYMP | Phase 1 | Breast Cancer | – |
Colorectal Cancer Metastatic (2) Esophageal Squamous Cell Carcinoma (ESCC) (2) Metastatic Colorectal Cancer (2) Rectal Cancer (1) Colorectal Adenocarcinoma (1) Breast Cancer (1) Gastric and Gastroesophageal Junction Adenocarcinoma (1) Colo-rectal Cancer (1)
small molecule (5), antibody (3), mixed (1)
Sun Yat-sen University (1) First Affiliated Hospital of Zhejiang University (1) Emory University (1) Gruppo Oncologico del Nord-Ovest (1) GERCOR - Multidisciplinary Oncology Cooperative Group (1) Qilu Hospital of Shandong University (1) National University Hospital, Singapore (1) Yonsei University (1) Ruijin Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.